Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Sexual Health · Peptide

Gonadorelin

Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH). Used to maintain testicular function during testosterone replacement therapy and to evaluate pituitary function.

Category: Sexual Health Last updated 2026-06-19
Gonadorelin at a glance

Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone (GnRH). Used to maintain testicular function during testosterone replacement therapy and to evaluate pituitary function. Mechanism: Synthetic GnRH. Typical route: Subcutaneous, IV. FDA status: Factrel (gonadorelin) was FDA-approved for diagnostic pituitary evaluation but was withdrawn from the U.S. market in 2018 by the manufacturer (not for safety reasons). Compounded gonadorelin is dispen

Drug classSynthetic GnRH
Half-life~2-10 minutes (parenteral)
RouteSubcutaneous, IV
Common dosing100-200 mcg, 2-3x/week
FDA statusWithdrawn (commercial); compounded available
Available throughCompounding pharmacies

Mechanism of action

Gonadorelin binds the GnRH receptor on pituitary gonadotrophs, stimulating LH and FSH release. In men on testosterone replacement, gonadorelin is used to maintain testicular size and intra-testicular testosterone production by preserving the LH signal that exogenous testosterone otherwise suppresses.

Dosing reference

Subcutaneous: 100-200 mcg, two to three times weekly for testicular-function maintenance during TRT. Diagnostic dosing for pituitary evaluation uses single 100 mcg IV doses. Dosing for fertility protocols varies.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Factrel (gonadorelin) was FDA-approved for diagnostic pituitary evaluation but was withdrawn from the U.S. market in 2018 by the manufacturer (not for safety reasons). Compounded gonadorelin is dispensed by pharmacies for off-label TRT-adjunct use.

U.S. telehealth providers that work with Gonadorelin

#1 of 3
88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →
#2 of 3
76/100v3.0 six-pillar rubric

Starting at $149/mo. Maximus is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →
#3 of 3
80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →

Related sexual-health peptides

Browse the full Sexual Health category →

Frequently asked questions about Gonadorelin

Is gonadorelin a replacement for HCG?

Gonadorelin and HCG both maintain testicular function during TRT but through different mechanisms. HCG mimics LH directly at the testes; gonadorelin works upstream by triggering the pituitary's own LH/FSH release. HCG has historically been more common; gonadorelin is increasingly used as a U.S.-compounding alternative.

Why isn't gonadorelin available as a branded product?

Factrel was withdrawn from the U.S. market in 2018 due to commercial decisions, not safety. Compounding pharmacies continue to dispense gonadorelin for off-label use.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing